Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas
暂无分享,去创建一个
R. Gascoyne | D. Scott | L. Sehn | J. Connors | K. Savage | G. Slack | D. Villa | A. Gerrie | R. Kansara
[1] N. Bartlett,et al. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. , 2015, Blood.
[2] K. Bendix,et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] J. Cerhan,et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Angrilli,et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[6] J. Connors,et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Cavalli,et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma , 2012, British journal of haematology.
[8] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[9] G. Salles,et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. , 2009, Journal of the National Cancer Institute.
[10] M. Ghielmini,et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. , 2010, Journal of the National Cancer Institute.
[11] R. Gascoyne,et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Randy D Gascoyne,et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Calaminici,et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[15] D. Arber,et al. Bone Marrow Biopsy Involvement by Non-Hodgkin's Lymphoma: Frequency of Lymphoma Types, Patterns, Blood Involvement, and Discordance With Other Sites in 450 Specimens , 2005, American Journal of Surgical Pathology.